Leptin therapy in patients with lipodystrophy and ayndromic insulin resistance

Leptin: Regulation and Clinical Applications

Volumn , Issue , 2015, Pages 225-236

  Brown, Rebecca J ^a   Gorden, Phillip ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Ectopic lipid; Insulin resistance; Leptin; Lipoatrophic diabetes; Lipodystrophy; Metreleptin; Myalept; NAFLD; Triglyceride

Indexed keywords

EID: 84944517417     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-09915-6_18     Document Type: Chapter

References (49)

1. Rother KI, Brown RJ. Novel forms of lipodystrophy: why should we care? Diabetes Care. 2013;36(8): 2142–5. PubMed PMID: 23881965. PubMed Central PMCID: 3714480.
2. Garg A. Clinical review#: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313–25. PubMed PMID: 21865368. Epub 2011/08/26. eng.
3. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093–103. PubMed PMID: 12393845. PubMed Central PMCID: 150795. Epub 2002/10/24. eng.
4. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356(3):237–47. PubMed PMID: 17229951. PubMed Central PMCID: 2670197. Epub 2007/01/19. eng.
5. Gorden P, Lupsa BC, Chong AY, Lungu AO. Is there a human model for the ‘metabolic syndrome’ with a defined aetiology? Diabetologia. 2010;53(7):1534–6. PubMed PMID: 20401463. Epub 2010/04/20. eng.
6. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53(1):27–35. PubMed PMID: 19727665. Epub 2009/09/04. eng.
7. Gorden P, Zadeh ES, Cochran E, Brown RJ. Syndromic insulin resistance: models for the therapeutic basis of the metabolic syndrome and other targets of insulin resistance. Endocr Pract. 2012;18(5):763–71. PubMed PMID: 23047930.
8. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570–8. PubMed PMID: 11856796. Epub 2002/02/22. eng.
9. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401(6748):73–6. PubMed PMID: 10485707. Epub 1999/09/15. eng.
10. Hidaka S, Yoshimatsu H, Kondou S, Tsuruta Y, Oka K, Noguchi H, et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J. 2002;16(6):509–18. PubMed PMID: 11919153. Epub 2002/03/29. eng.
11. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4):513–9. PubMed PMID: 15045701. Epub 2004/03/27. eng.
12. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345–50. PubMed PMID: 12021250. PubMed Central PMCID: 150981. Epub 2002/05/22. eng.
13. Aotani D, Ebihara K, Sawamoto N, Kusakabe T, Aizawa-Abe M, Kataoka S, et al. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab. 2012;97(10):3663–71. PubMed PMID: 22872692. PubMed Central PMCID: 3462942.
14. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26(1):30–5. PubMed PMID: 12502655. Epub 2002/12/28. eng.
15. Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131–7. PubMed PMID: 23439261.
16. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92(2):532–41. PubMed PMID: 17118991. Epub 2006/11/23. eng.
17. Ebihara K, Masuzaki H, Nakao K. Long-term leptinreplacement therapy for lipoatrophic diabetes. N Engl J Med. 2004;351(6):615–6. PubMed PMID: 15295061.
18. Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922–32. PubMed PMID: 22068254. PubMed Central PMCID: 3498767.
19. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54(7):1994–2002. PubMed PMID: 15983199. Epub 2005/06/29. eng.
20. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism. 2007;56(4):508–16. PubMed PMID: 17379009. PubMed Central PMCID: 2595136. Epub 2007/03/24. eng.
21. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879–84. PubMed PMID: 10486419. Epub 1999/09/16. eng.
22. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O’Kirwan F, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A. 2004;101(13):4531–6. PubMed PMID: 15070752. PubMed Central PMCID: 384781.
23. Oral EA, Ruiz E, Andewelt A, Sebring N, Wagner AJ, Depaoli AM, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab. 2002; 87(7):3110–7. PubMed PMID: 12107209. Epub 2002/07/11. eng.
24. Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005;54(2):255–63. PubMed PMID: 15690321. Epub 2005/02/04. eng.
25. Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2012;97(2):563–7. PubMed PMID: 22090274. PubMed Central PMCID: 3275358. Epub 2011/11/18. eng.
26. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011;301(4):E567–84. PubMed PMID: 21791620. PubMed Central PMCID: 3191548.
27. Mantzoros CS, Ozata M, Negrao AB, Suchard MA, Ziotopoulou M, Caglayan S, et al. Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans. J Clin Endocrinol Metab. 2001;86(7):3284–91. PubMed PMID: 11443202.
28. Paz-Filho G, Delibasi T, Erol HK, Wong ML, Licinio J. Congenital leptin deficiency and thyroid function. Thyroid Res. 2009;2(1):11. PubMed PMID: 19889232. PubMed Central PMCID: 2776005.
29. Motyl KJ, Rosen CJ. Understanding leptin-dependent regulation of skeletal homeostasis. Biochimie. 2012;94(10):2089–96. PubMed PMID: 22534195. PubMed Central PMCID: 3512082.
30. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197–207. PubMed PMID: 10660043. Epub 2000/02/05. eng.
31. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone. 2004;34(3):376–83. PubMed PMID: 15003785. Epub 2004/03/09. eng.
32. Iwaniec UT, Boghossian S, Lapke PD, Turner RT, Kalra SP. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides. 2007;28(5):1012–9. PubMed PMID: 17346852. PubMed Central PMCID: 1986832. Epub 2007/03/10. eng.
33. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res. 2005;20(6):994–1001. PubMed PMID: 15883640. Epub 2005/05/11. eng.
34. Christensen JD, Lungu AO, Cochran E, Collins MT, Gafni RI, Rother KI, et al. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J Clin Endocrinol Metab. 2014. PubMed PMID: 25070319.
35. Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199–207. PubMed PMID: 15240593. Epub 2004/07/09. eng.
36. Oral EA, Javor ED, Ding L, Uzel G, Cochran EK, Young JR, et al. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab. 2006;91(2):621–8. PubMed PMID: 16317060. Epub 2005/12/01. eng.
37. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profi le in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006;91(7):2605–11. PubMed PMID: 16636130.
38. Magkos F, Brennan A, Sweeney L, Kang ES, Doweiko J, Karchmer AW, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism. 2011;60(7):1045–9. PubMed PMID: 21081243. PubMed Central PMCID: 3057303. Epub 2010/11/18. eng.
39. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009;94(4):1137–44. PubMed PMID: 19174500. PubMed Central PMCID: 2682465.
40. Sekhar RV, Jahoor F, Iyer D, Guthikonda A, Paranilam J, Elhaj F, et al. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism. 2012;61(10):1395–403. PubMed PMID: 22542724.
41. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med. 1976;294(14):739–45. PubMed PMID: 176581.
42. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson- Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore). 2004;83(4):209–22. PubMed PMID: 15232309.
43. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119(2):315–22. PubMed PMID: 19164855. PubMed Central PMCID: 2631303. Epub 2009/01/24. eng.
44. Semple RK, Williams RM, Dunger DB. What is the best management strategy for patients with severe insulin resistance? Clin Endocrinol (Oxf). 2010;73(3):286–90. PubMed PMID: 20455892.
45. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab. 2004;89(4):1548–54. PubMed PMID: 15070911.
46. Brown RJ, Cochran E, Gorden P. Metreleptin improves blood glucose in patients with insulin receptor mutations. J Clin Endocrinol Metab. 2013;22. PubMed PMID: 23969187.
47. Aslam A, Savage DB, Coulson IH. Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infi ltration. Int J Dermatol. 2013;29. PubMed PMID: 24168394.
48. Yiannias JA, DiCaudo DJ, Maskin E. Peripheral T-cell lymphoma presenting as lipoatrophy and nodules. Int J Dermatol. 2006;45(12):1415–9. PubMed PMID: 17184242.
49. LaBreque D. World Gastroenterology Organisation Global Guidelines on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis 2012. 3/13/2014. Available from http://www.worldgastroenterology.org/assets/export/userfiles/2012_NASH%20and%20NAFLD_Final_long.pdf